⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523283 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL25395133 | 0.96 | — | — | |
| SCHEMBL1829357 | 0.92 | — | — | |
| SCHEMBL18207810 | 0.88 | — | — | |
| SCHEMBL19143046 | 0.88 | ALDH1A1 (0.41) | — | |
| SCHEMBL550429 | 0.87 | — | — | |
| SCHEMBL14545648 | 0.87 | — | — | |
| SCHEMBL1950400 | 0.84 | KDM4E (0.45) | — | |
| SCHEMBL25097384 | 0.84 | KDM4E (0.40) | — | |
| SCHEMBL2085050 | 0.84 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 707 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | claimed |
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119768392-A | Aryl or heteroaryl substituted glutarimide derivatives and uses thereof | 标新生物医药科技(上海)有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119654316-A | Thioglutarimide isoindolinone skeleton-based compound and application thereof | 标新生物医药科技(上海)有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119451952-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | claimed |
| CN-118556047-A | Oxo-isoindolinyl substituted piperidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2024-08-27 | — | — | CN | claimed |
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| CN-117881668-A | Compound based on isoindoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | claimed |
| CN-116589445-A | Compound based on quinazoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | claimed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | claimed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | claimed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | claimed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070278-A | Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof | 标新生物医药科技(上海)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122029160-A | Method for preparing PI3K inhibitor | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260106218-A1 | POLYMER ELECTROLYTE AND ELECTROCHEMICAL DEVICE COMPRISING SAME | FACTORIAL INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062401-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | NEUMORA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048045-A1 | PI3K-ALPHA INHIBITORS FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4690339-A2 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES THEREOF | Factorial Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2026-01-22 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4676931-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025264523-A1 | ELECTROLYTE COMPRISING FOUR OR MORE SALTS AND LITHIUM METAL BATTERIES COMPRISING SAME | FACTORIAL INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250340575-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4143183-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4633735-A1 | INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-4626878-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4611890-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4602043-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598919-A1 | METHODS FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598927-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12371414-B2 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4587029-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES | Invea Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4584273-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250206746-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250206714-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES | INVEA THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2025137469-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250197391-A1 | METHODS OF SYNTHESIZING EGFR INHIBITORS | ANTARES THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-120136870-A | GLP-1 receptor targeting compounds and uses thereof | 信达生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025119206-A1 | GLP-1 RECEPTOR TARGETING COMPOUNDS AND USES THEREOF | FORTVITA BIOLOGICS INC. (KY) | 2025-06-12 | — | — | WO | disclosed |
| US-20250188103-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250177362-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250171466-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4559905-A2 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| WO-2025104443-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4551571-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025093881-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025093870-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4097099-B9 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119874775-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025085725-A1 | METHODS FOR TREATING A P53-ASSOCIATED CANCER | SCORPION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085703-A1 | METHODS FOR TREATING P53-ASSOCIATED CANCER | SCORPION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540238-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119841865-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4536637-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119823184-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250115582-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250115595-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | THE JOHNS HOPKINS UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250115606-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119768392-A | Aryl or heteroaryl substituted glutarimide derivatives and uses thereof | 标新生物医药科技(上海)有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-119735540-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| CN-119698415-A | Methods of synthesizing EGFR inhibitors | 蝎子疗法股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025038699-A9 | PROCESSES OF PREPARING PI3K INHIBITORS | SCORPION THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119654316-A | Thioglutarimide isoindolinone skeleton-based compound and application thereof | 标新生物医药科技(上海)有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2025054366-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054187-A1 | TGR5 ANTAGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-113683610-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025038699-A1 | PROCESSES OF PREPARING PI3K INHIBITORS | SCORPION THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4508047-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119451952-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12221442-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-113683611-B | Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2025026422-A1 | ARYL OR HETEROARYL SUBSTITUTED GLUTARIMIDE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4499635-A1 | METHODS OF SYNTHESIZING EGFR INHIBITORS | Scorpion Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4496797-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | Gasherbrum Bio, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016351-A1 | COMPOUND BASED ON THIO-GLUTARIMIDO ISOINDOLINONE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119343343-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4490155-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4486722-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-113382772-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119255988-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119176808-A | GLP-1 agonist and preparation method and application thereof | 山东法恩新材料科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024259121-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024259116-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| EP-4476216-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4476213-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119137101-A | Compounds, compositions, and methods | 尼科治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024245444-A1 | OXOISOINDOLINYL-SUBSTITUTED TETRAHYDROPYRIMIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119072474-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-112823151-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024229121-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4458834-A2 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12134625-B2 | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240343728-A1 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| CN-111285873-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113620944-B | Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-115698003-B | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024211797-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024206364-A2 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES THEREOF | FACTORIAL INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240332614-A1 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES THEREOF | FACTORIAL INC. | 2024-10-03 | — | — | US | disclosed |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | LIBRA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240294492-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-09-05 | — | — | US | disclosed |
| EP-4419505-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR | Arena Pharmaceuticals, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556048-A | Sulfur/oxygen substituted glutarimide isoindolinone skeleton-based compound and application thereof | 标新生物医药科技(上海)有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118556047-A | Oxo-isoindolinyl substituted piperidinedione derivative and application thereof | 标新生物医药科技(上海)有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-113620945-B | RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines | 广东东阳光药业股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4415816-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118488954-A | Pyrrolo [2,1-F ] [1,2,4] triazine derivatives as DYRK1A inhibitors | 拜斯丽治疗有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112574236-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-111285874-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-112442050-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12049460-B2 | EGFR inhibitor compounds | RECURIUM IP HOLDINGS, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240246962-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240246928-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. | 2024-07-25 | — | — | US | disclosed |
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4097099-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024126987-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199649-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4384164-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | The Johns Hopkins University (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118159534-A | Compounds that inhibit PI3K isoform alpha and methods for treating cancer | 蝎子疗法股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024119067-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | Neumora Therapeutics, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4376845-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-11993580-B1 | Methods of treating neurological disorders | Neumora Therapeutics, Inc. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024104968-A1 | PYRAZOLOPYRROLOPYRIDAZINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024097391-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4363414-A1 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086804-A1 | INDOLIZINE DERIVATIVES FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081889-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-117881668-A | Compound based on isoindoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024077273-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077036-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240101589-A1 | INHIBITORS OF METTL3 | EVOTEC INTERNATIONAL GMBH (DE) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059085-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES | INVEA THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024054540-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11926643-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11926626-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897871-B1 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2024030863-A1 | PI3K-ALPHA INHIBITORS FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11866422-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2024-01-09 | — | — | US | disclosed |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247590-A1 | TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247596-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023244818-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230391770-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023198140-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4257191-A2 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023183601-A1 | METHODS OF SYNTHESIZING EGFR INHIBITORS | SCORPION THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023179542-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO , INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230286945-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023169456-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4236937-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4232431-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230265091-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229049-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116615430-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | LIEBER INSTITUTE, INC. | 2023-08-17 | — | — | US | disclosed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151574-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116589445-A | Compound based on quinazoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023141852-A1 | CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 益方生物科技(上海)股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4214208-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | The Johns Hopkins University (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4211133-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4211139-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023131118-A1 | PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF | 上海科技大学 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| EP-4204415-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11691135-B2 | Synthesis of alkynones via carbonylative Sonogashira coupling reactions catalyzed by Pd(II)-N-Heterocyclic carbene-pyridine complexes | KING FAHD UNIVERSITY OF PETROLEUM & MINERALS (SA) | 2023-07-04 | — | — | US | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109802-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023105303-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | KASHIV BIOSCIENCES, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| EP-4192831-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023067520-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT 2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-04-06 | — | — | US | disclosed |
| US-20230107793-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-109563033-B | Aliphatic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4153186-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | Argorna Pharmaceuticals Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20230071840-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018636-A1 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018747-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-20230047905-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-4129989-A1 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | disclosed |
| CN-115698003-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697999-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-01-05 | — | — | US | disclosed |
| EP-4112619-A1 | NOVEL USE OF MULTIKINASE INHIBITOR | Transthera Sciences (Nanjing), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4103563-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115466272-A | Pyrimido-heterocyclic compound, pharmaceutical composition containing pyrimido-heterocyclic compound and application of pyrimido-heterocyclic compound | 博瑞生物医药（苏州）股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220388957-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4097099-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11492365-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-109311819-B | Isoquinolin-3-yl carboxamides, their preparation and their use | 萨穆梅德有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220332698-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022197913-A1 | BICYCLIC DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | Recordati Industria Chimica e Farmacentica S.p.A. (IT) | 2022-09-13 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220267306-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022155814-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS LTD (CN) | 2022-07-28 | — | — | WO | disclosed |
| US-20220227760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-07-21 | — | — | US | disclosed |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114685453-A | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022135442-A1 | CDK2 INHIBITOR AND PREPARATION METHOD THEREFOR | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-11352358-B2 | FXR agonist | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-4006030-A2 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11339103-B2 | Continuous flow processes for making bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022098992-A1 | USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093849-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022094271-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135557-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| WO-2022083703-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022081953-A1 | SYNTHESIS OF ALKYNONES VIA CARBONYLATIVE SONOGASHIRA COUPLING REACTIONS CATALYZED BY PD(II)-N-HETEROCYCLIC CARBENE-PYRIDINE COMPLEXES | SAUDI ARABIAN OIL COMPANY (SA) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081984-A1 | METHODS AND COMPOUNDS TO TREAT SARS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078380-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220119433-A1 | SYNTHESIS OF BIARYL KETONES AND BIARYL DIKETONES VIA CARBONYLATIVE SUZUKI-MIYAURA COUPLING REACTIONS CATALYZED BY BRIDGED BIS(N-HETEROCYCLIC CARBENE)PALLADIUM(II) CATALYSTS | KING FAHD UNIVERSITY OF PETROLEUM & MINERALS (SA) | 2022-04-21 | — | — | US | disclosed |
| US-20220118435-A1 | SYNTHESIS OF ALKYNONES VIA CARBONYLATIVE SONOGASHIRA COUPLING REACTIONS CATALYZED BY PD(II)-N-HETEROCYCLIC CARBENE-PYRIDINE COMPLEXES | KING FAHD UNIVERSITY OF PETROLEUM & MINERALS (SA) | 2022-04-21 | — | — | US | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3983383-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022074391-A1 | COMPOUNDS INHIBITORS OF METTL3 | STORM THERAPEUTICS LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074379-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022072645-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022072632-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3976584-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022060805-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022060816-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| WO-2022060799-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220081409-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2022048665-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-11267803-B2 | Carbocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220062240-A1 | METHODS OF TREATING CANCER USING A CLK INHIBITOR | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-03 | — | — | US | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2022028572-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3939588-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | Transthera Sciences (Nanjing), Inc. (CN) | 2022-01-19 | — | — | EP | disclosed |
| EP-3454945-B1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-11192912-B1 | Synthesis of biaryl ketones and biaryl diketones via carbonylative Suzuki-Miyaura coupling reactions catalyzed by bridged bis(N-heterocyclic carbene)palladium(II) catalysts | KING FAHD UNIVERSITY OF PETROLEUM & MINERALS (SA) | 2021-12-07 | — | — | US | disclosed |
| EP-3915992-A1 | PDE9 INHIBITOR AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2021-12-01 | — | — | EP | disclosed |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3911317-A2 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | BioSplice Therapeutics, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911314-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210347762-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3898626-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898615-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3303317-B1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY INC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3883651-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-11091465-B2 | — | — | 2021-08-17 | — | — | US | disclosed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-11046679-B2 | Indoleamine 2,3-dioxygenase inhibitor and application | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20210177828-A1 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3808748-A1 | SUBSTITUTED PIPERIDINES AS CXCR4-INHIBITORS | X4 Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210107917-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210101908-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021067805-A1 | OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067791-A1 | OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021057970-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057963-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574236-A | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2021043209-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20210061730-A1 | CONTINUOUS FLOW PROCESSES FOR MAKING BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2021-03-04 | — | — | US | disclosed |
| EP-3448386-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20210047320-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210024522-A1 | FXR AGONIST | XUANZHU (SHIJIAZHUANG) BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-01-28 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200385362-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2020-12-10 | — | — | US | disclosed |
| EP-3471727-B1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| WO-2020243519-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020236586-A1 | N-HETARYL-SQUARAMIDE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2020-11-05 | — | — | US | disclosed |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-10-29 | — | — | US | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200299263-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2020-09-24 | — | — | US | disclosed |
| US-10781218-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10759799-B2 | Indazole containing macrocycles and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759796-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10744128-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200255414-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020156271-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | 江苏威凯尔医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-20200246474-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-08-06 | — | — | US | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2020150552-A2 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150417-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150439-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2020131627-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-3665142-A1 | CONTINUOUS FLOW PROCESSES FOR MAKING BICYCLIC COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181131-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| US-20200165224-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2020-05-28 | — | — | US | disclosed |
| US-20200155540-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | HEPATIKOS THERAPEUTICS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10653688-B2 | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| EP-3650449-A1 | FXR RECEPTOR AGONIST | Xuanzhu (Hainan) Biopharmaceutical Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200123150-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10604514-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-10544128-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190322671-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2019-10-24 | — | — | US | disclosed |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10413537-B2 | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190233396-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2019-08-01 | — | — | US | disclosed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | disclosed |
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3504217-A1 | METHODS FOR CROSS COUPLING | Zeno Royalties & Milestones, LLC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-20 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190142799-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190144442-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| US-20190125740-A1 | 6-(6-MEMBERED HETEROARYL & ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
| US-20190125741-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL-(5-MEMBERED HETEROARYL) CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
| WO-2019079626-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119263-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-04-25 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3472149-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3472151-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3464275-A1 | EGFR INHIBITOR COMPOUNDS | Zeno Royalties & Milestones, LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-03-28 | — | — | US | disclosed |
| WO-2019059344-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | 大日本住友製薬株式会社 | 2019-03-28 | — | — | WO | disclosed |
| WO-2019051038-A1 | CONTINUOUS FLOW PROCESSES FOR MAKING BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019035008-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| US-10208042-B1 | Multi-kinase inhibitor compound, and crystal form and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| WO-2019029541-A1 | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-02-14 | — | — | WO | disclosed |
| US-20190040064-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2019-02-07 | — | — | US | disclosed |
| WO-2019007418-A1 | FXR RECEPTOR AGONIST | 山东轩竹医药科技有限公司 | 2019-01-10 | — | — | WO | disclosed |
| US-10174041-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10106527-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-10100038-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180222887-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180208580-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-26 | — | — | US | disclosed |
| US-20180201614-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2018-07-19 | — | — | US | disclosed |
| WO-2018106571-A1 | ANTIFUNGAL COMPOUNDS AND METHODS | KALYRA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| EP-3294737-A1 | BICYCLIC COMPOUNDS | Kalyra Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-02-08 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222915-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017222914-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170360794-A1 | JAK INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2017-12-21 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9834549-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
| WO-2017205459-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017197240-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017188287-A1 | SUBSTITUTED PURINE DERIVATIVE | 大日本住友製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| WO-2017189829-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| WO-2017161028-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161002-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-3193605-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3193603-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| EP-2526102-B1 | Inhibitors of PI3 kinase | FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-20170050989-A1 | Molecular Imaging Probes | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-02-23 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| WO-2016195776-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197027-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| WO-2016183094-A1 | BICYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| EP-3080124-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
| EP-3077009-A1 | MOLECULAR IMAGING PROBES | The General Hospital Corporation (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016157052-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160251346-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-09-01 | — | — | US | disclosed |
| EP-2197874-B1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-9365564-B2 | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-14 | — | — | US | disclosed |
| US-20160145244-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMA, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-9346852-B2 | Substituted adipic acid amides and uses thereof | BRISTOL-MYERS SCUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2016040498-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040515-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2419432-B9 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9260439-B2 | Dihydropyrrolopyrimidine derivatives | PFIZER INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150291604-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015155624-A1 | DIHYDROPYRROLOPYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015085005-A1 | MOLECULAR IMAGING PROBES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2563780-B1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11(BETA)-HSD1 | UNIV EDINBURGH (GB) | 2015-05-06 | — | — | EP | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2288601-B1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8815909-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-8710049-B2 | Diaminocyclohexane compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2718283-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2419429-B1 | IMIDAZOPYRAZINES AS INHIBITORS OF PROTEIN KINASES | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2419432-B1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20130184284-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184262-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130123268-A1 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-05-16 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2013064919-A1 | QUINAZOLINE DERIVATIVES WITH HSP90 INHIBITORY ACTIVITY | DAC SRL (IT) | 2013-05-10 | — | — | WO | disclosed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8410276-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410276-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2563780-A1 | 3, 3 -DISUBSTITUTED- ( 8 - AZA - BICYCLO [3.2.1]OCT- 8 - YL) -[5- (1H - PYRAZOL - 4 -YL) -THIOPHEN-3 -YL]METHANONES AS INHIBITORS OF 11 (BETA) -HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| WO-2013016411-A1 | NOVEL FLUORINATED CYCLIC SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE | SMITH GARRY ROBERT (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013012829-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012827-A1 | DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
| EP-2524918-A1 | Imidazopyrazines derivates as kinase inhibitors | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-21 | — | — | EP | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| WO-2012125622-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2012052745-A1 | COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-04-26 | — | — | WO | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-8143404-B2 | N-heterocycle urea compounds such as 5-([(butyl{1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy)-3-pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino)-2,4-difluorobenzamide; chemokine receptor CCR5 antagonists for various inflammatory diseases, autoimmune diseases, infectious diseases | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143404-B2 | N-heterocycle urea compounds such as 5-([(butyl{1-[(2-methyl-6-{4-[(methylsulfonyl)amino]phenoxy)-3-pyridinyl)methyl]-4-piperidinyl}amino)carbonyl]amino)-2,4-difluorobenzamide; chemokine receptor CCR5 antagonists for various inflammatory diseases, autoimmune diseases, infectious diseases | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-27 | — | — | US | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2419429-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| EP-2385040-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO Pharmaceutical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| WO-2011135276-A1 | 3, 3 -DISUBSTITUTED- ( 8 - AZA - BICYCLO [3.2.1] OCT- 8 - YL) -[5- (1H - PYRAZOL - 4 -YL) -THIOPHEN-3 -YL] METHANONES AS INHIBITORS OF 11 (BETA) -HSD1 | THE UNIVERSITY OF EDINBURGH (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| WO-2011089400-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-28 | — | — | WO | disclosed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-7910741-B2 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910741-B2 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| WO-2010119264-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) | 2010-10-21 | — | — | WO | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2212333-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| EP-2158207-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. Hoffmann-Roche AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009052145-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080057074-A1 | Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080057074-A1 | Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20070270429-A1 | Function Inhibitor of Effector Cell | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270429-A1 | Function Inhibitor of Effector Cell | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1790637-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006130426-A2 | MODULATORS OF CCR-5 ACTIVITY | KEMIA, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-5407938-A | Treating central nervous system disorders; Alzheimer*s | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-04-18 | — | — | US | disclosed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | disclosed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | disclosed |